



A monthly report summarizing life science transactions in Washington State.

BY THE NUMBERS: (YTD) **94** TRANSACTIONS **TOTALING OVER** **\$4.65B**



OCTOBER TOP TRANSACTIONS

Mozart Therapeutics has secured \$55M to develop therapies for celiac disease and other immune-related conditions. The funding will help propel Mozart's lead compound through preclinical studies to human testing, with trials for celiac disease expected to start in 2024 ([GeekWire](#)).

Viome Life Sciences has raised \$54M to bolster the company's efforts to develop cancer diagnostics and support its separate consumer product division. Viome's consumer division offers services to analyze the microbiome, the collection of microbes in the gut and other parts of the body ([GeekWire](#)).

Cyrus Biotechnology, a University of Washington & Institute for Protein Design spinout, has raised \$15,942,168.00 in new funding. Cyrus Bio offers easy-to-use Computational Protein Engineering software on the cloud, accessed via a web-based GUI. They accelerate discovery and development in Biotech, Pharmaceuticals, and Industrial Biotechnology ([Intelligence360](#)).

OTHER TRENDS & HIGHLIGHTS

Life Science Economic Activity in Washington state is strong and growing. A recent report by Life Science Washington shows a 23.5% increase in jobs in the field from 2015 to 2019. More than 39,000 people are employed in life science jobs in the state, at an average annual wage of \$106,122 ([Life Science Washington](#)).

Immusoft will collaborate with pharma giant Takeda to develop treatments targeted to the central nervous system in a deal worth potentially more than \$900M. Immusoft's technology involves engineering a patient's B cells to mass produce therapeutic proteins ([GeekWire](#)).

Gates Foundation pledges \$120M to support access for a Covid-19 pill. The drug, molnupiravir, is an investigational antiviral pill from pharmaceutical giant Merck & Co. in collaboration with Ridgeback Biotherapeutics. The Gates Foundation said its donation will be used to develop, produce and distribute generic versions of the drug ([Puget Sound Business Journal](#)).

TRANSACTIONS

Date	Company	Sector	Type	Amount	Location
01-Oct-2021	Anavasi Diagnostics	Medtech	Angel (individual)	\$6,000,000	Seattle
04-Oct-2021	Kineta	Biotech	Later Stage VC	undisclosed	Seattle
05-Oct-2021	Cyrus Biotechnology	Digital Health	Later Stage VC	\$15,940,000	Seattle
06-Oct-2021	MicrobiomX	Medtech	Seed Round	\$3,500,000	Seattle
08-Oct-2021	Tegria	Digital Health	Angel (individual)	\$7,320,000	Renton
19-Oct-2021	LumiThera	Medtech	Later Stage VC	\$4,520,000	Poulsbo
19-Oct-2021	Seal Rock Therapeutics	Biotech	Later Stage VC	undisclosed	Seattle
26-Oct-2021	Mozart Therapeutics	Biotech	Early Stage VC	\$55,000,000	Seattle
31-Oct-2021	Viome Life Sciences	Biotech	Later Stage VC	\$54,000,000	Bellevue
October Total (disclosed transactions):				\$146,280,000	
September Total (disclosed transactions):				\$84,970,000	
August Total (disclosed transactions):				\$104,260,000	
July Total (disclosed transactions):				\$660,550,000	
June Total (disclosed transactions):				\$572,110,000	
May Total (disclosed transactions):				\$14,530,000	
April Total (disclosed transactions):				\$841,190,000	
March Total (disclosed transactions):				\$1,089,960,000	
February Total (disclosed transactions):				\$666,580,000	
January Total (disclosed transactions):				\$478,070,000	